VWM
OCUL icon

Vigilare Wealth Management’s Ocular Therapeutix OCUL Stock Holding History

Vigilare Wealth Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,470
Closed -$150K – 155
2021
Q4 		$150K Sell
21,470
-19,950
-48% -$155K 0.09% 173
2021
Q3 		$414K Buy
41,420
+9,830
+31% +$110K 0.26% 108
2021
Q2 		$448K Buy
31,590
+8,430
+36% +$128K 0.27% 103
2021
Q1 		$380K Buy
23,160
+9,635
+71% +$186K 0.27% 103
2020
Q4 		$280K Sell
13,525
-4,675
-26% -$69.4K 0.27% 88
2020
Q3 		$139K Buy
18,200
+900
+5% +$7.47K 0.14% 127
2020
Q2 		$144K Buy
+17,300
New +$115K 0.15% 116

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Vigilare Wealth Management's OCUL Position: Q1 2022 in Review

Vigilare Wealth Management sold out of Ocular Therapeutix (OCUL) in Q1 2022, closing a stake of 21,470 shares — an estimated $150K sold.

Vigilare Wealth Management first reported a position in OCUL in Q2 2020 and held it in 7 quarters. The position peaked at $448K in Q2 2021. 132 funds tracked by Wall St. Rank hold OCUL as of Q1 2022.

  • Vigilare Wealth Management reported no remaining Ocular Therapeutix position as of Q1 2022 after selling out during the quarter.
  • Vigilare Wealth Management sold 21,470 Ocular Therapeutix shares in Q1 2022, an estimated $150K.
  • Vigilare Wealth Management first reported a position in Ocular Therapeutix in Q2 2020 and held it in 7 quarters.
  • Vigilare Wealth Management's Ocular Therapeutix position peaked at $448K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2022.

Based on Vigilare Wealth Management's 13F filing for Q1 2022, filed 6 Apr 2022.